Shattuck Labs, Inc.

NASDAQ:STTK

3.81 (USD) • At close September 13, 2024
Bedrijfsnaam Shattuck Labs, Inc.
Symbool STTK
Munteenheid USD
Prijs 3.81
Beurswaarde 181,841,013
Dividendpercentage 0%
52-weken bereik 1.33 - 11.76
Industrie Biotechnology
Sector Healthcare
CEO Dr. Taylor H. Schreiber M.D., Ph.D.
Website https://www.shattucklabs.com

An error occurred while fetching data.

Over Shattuck Labs, Inc.

Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that

Vergelijkbare Aandelen

OncoCyte Corporation logo

OncoCyte Corporation

OCX

3.08 USD

MediciNova, Inc. logo

MediciNova, Inc.

MNOV

1.82 USD

MDxHealth SA logo

MDxHealth SA

MDXH

2.375 USD

Olema Pharmaceuticals, Inc. logo

Olema Pharmaceuticals, Inc.

OLMA

12.7 USD

Jasper Therapeutics, Inc. logo

Jasper Therapeutics, Inc.

JSPR

22.75 USD

Werewolf Therapeutics, Inc. logo

Werewolf Therapeutics, Inc.

HOWL

2.34 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)